Global Health Partner reported financial results for Q1 2012 with the following highlights:
- Revenue increased 8% to SEK 192 million due to growth in all service lines except Bariatrics.
- Operating result decreased to SEK 5 million from continued tough market conditions in Bariatrics.
- Profitability was also impacted by SEK 2.6 million in acquisition costs for a recent Danish acquisition.
- Performance was strong in Swedish Spine, Orthopaedics, Dental and Arrhythmia clinics.
Global Health Partner reported strong financial performance in Q4 2012 with all-time high revenues of 206 MSEK, a 10% growth over the previous year. However, the full year 2012 results were weak due to poor performance in Q2 and Q3, with revenues of 723 MSEK, a 7% growth but 0% organic growth. Actions taken included divestments of non-core businesses and investments to strengthen core businesses. While market conditions remained tough with price pressure, measures implemented throughout 2012 have started to improve profitability and cash flow.
Este documento presenta la hoja de vida de Diego Banderas, un estudiante de medicina de la Escuela Superior Politécnica de Chimborazo. Incluye sus datos personales como nombre, fecha de nacimiento, dirección y educación. Completó sus estudios primarios en la Escuela "La Salle" y secundarios en el Colegio "San Felipe Neri" con especialización químico-biológica. Actualmente estudia medicina en la Escuela Superior Politécnica de Chimborazo para obtener el título de Médico General.
Research in the digital age - circa 2005Larry Naukam
This document discusses the benefits of digitizing archival materials such as books, newspapers, photographs, and manuscripts that are fragile or at risk of damage from heavy use. It outlines several initiatives by the Rochester Public Library to make parts of its collection more accessible online, including digitizing photographs, maps, and genealogical records. The document also discusses important considerations for digital projects such as rights, costs, staffing needs, formats, and ensuring long-term access to and maintenance of the digital files.
El documento anuncia el VI Torneo Sansonia de Tiro con Arco que se celebrará el 31 de agosto de 2014 en Puebla de Sancho Pérez, Badajoz. Detalla las modalidades, categorías, distancias, horarios, inscripciones, cuotas e información de contacto. Las inscripciones deben enviarse antes del 28 de agosto adjuntando el justificante de pago.
Global Health Partner reported a 4% increase in revenue for Q2 2012 but profitability declined due to tough market conditions in bariatrics and temporary issues in orthopedics/spine. The profit margin decreased from 7.2% to -1.2% for the quarter. While some service lines like dental performed well, others such as bariatrics and orthopedics/spine faced headwinds from price pressures, tender losses, and lower patient volumes. Actions are being taken to reduce costs and adjust capacity to address the challenging market environment.
Global Health Partner reported disappointing Q3 performance with 7% revenue growth but negative EBIT of SEK -13 million. Market trends in Sweden include political focus on profits and quality, as well as increasing patient power and choice. Denmark faces continued price pressure and consolidation. Actions taken include focusing on core business, Nordic growth through acquisitions, and adjusting capacity and costs. Orthopedics/Spine revenue grew 11% in Q3 from an acquisition, but profitability was negatively impacted by lost contracts. Dental revenue was maintained despite market declines.
The document summarizes health reforms in OECD countries. It finds that while systems share some commonalities like universal coverage and defined benefits packages, they vary in their organization and financing. All systems are struggling with providing value for money as health costs rise faster than incomes. The document also examines reforms in areas like physician roles, quality improvement, health IT, pharmaceutical policies, and innovations in countries like Sweden and the UK.
Swedbank was founded in 1820, as Sweden’s first savings bank was established. Today, our heritage is visible in that we truly are a bank for each and every one and in that we still strive to contribute to a sustainable development of society and our environment. We are strongly committed to society as a whole and keen to help bring about a sustainable form of societal development. Our Swedish operations hold an ISO 14001 environmental certification, and environmental work is an integral part of our business activities.
Global Health Partner reported strong financial performance in Q4 2012 with all-time high revenues of 206 MSEK, a 10% growth over the previous year. However, the full year 2012 results were weak due to poor performance in Q2 and Q3, with revenues of 723 MSEK, a 7% growth but 0% organic growth. Actions taken included divestments of non-core businesses and investments to strengthen core businesses. While market conditions remained tough with price pressure, measures implemented throughout 2012 have started to improve profitability and cash flow.
Este documento presenta la hoja de vida de Diego Banderas, un estudiante de medicina de la Escuela Superior Politécnica de Chimborazo. Incluye sus datos personales como nombre, fecha de nacimiento, dirección y educación. Completó sus estudios primarios en la Escuela "La Salle" y secundarios en el Colegio "San Felipe Neri" con especialización químico-biológica. Actualmente estudia medicina en la Escuela Superior Politécnica de Chimborazo para obtener el título de Médico General.
Research in the digital age - circa 2005Larry Naukam
This document discusses the benefits of digitizing archival materials such as books, newspapers, photographs, and manuscripts that are fragile or at risk of damage from heavy use. It outlines several initiatives by the Rochester Public Library to make parts of its collection more accessible online, including digitizing photographs, maps, and genealogical records. The document also discusses important considerations for digital projects such as rights, costs, staffing needs, formats, and ensuring long-term access to and maintenance of the digital files.
El documento anuncia el VI Torneo Sansonia de Tiro con Arco que se celebrará el 31 de agosto de 2014 en Puebla de Sancho Pérez, Badajoz. Detalla las modalidades, categorías, distancias, horarios, inscripciones, cuotas e información de contacto. Las inscripciones deben enviarse antes del 28 de agosto adjuntando el justificante de pago.
Global Health Partner reported a 4% increase in revenue for Q2 2012 but profitability declined due to tough market conditions in bariatrics and temporary issues in orthopedics/spine. The profit margin decreased from 7.2% to -1.2% for the quarter. While some service lines like dental performed well, others such as bariatrics and orthopedics/spine faced headwinds from price pressures, tender losses, and lower patient volumes. Actions are being taken to reduce costs and adjust capacity to address the challenging market environment.
Global Health Partner reported disappointing Q3 performance with 7% revenue growth but negative EBIT of SEK -13 million. Market trends in Sweden include political focus on profits and quality, as well as increasing patient power and choice. Denmark faces continued price pressure and consolidation. Actions taken include focusing on core business, Nordic growth through acquisitions, and adjusting capacity and costs. Orthopedics/Spine revenue grew 11% in Q3 from an acquisition, but profitability was negatively impacted by lost contracts. Dental revenue was maintained despite market declines.
The document summarizes health reforms in OECD countries. It finds that while systems share some commonalities like universal coverage and defined benefits packages, they vary in their organization and financing. All systems are struggling with providing value for money as health costs rise faster than incomes. The document also examines reforms in areas like physician roles, quality improvement, health IT, pharmaceutical policies, and innovations in countries like Sweden and the UK.
Swedbank was founded in 1820, as Sweden’s first savings bank was established. Today, our heritage is visible in that we truly are a bank for each and every one and in that we still strive to contribute to a sustainable development of society and our environment. We are strongly committed to society as a whole and keen to help bring about a sustainable form of societal development. Our Swedish operations hold an ISO 14001 environmental certification, and environmental work is an integral part of our business activities.
This document provides an overview of a life science seminar presented by Topotarget A/S executives. It includes a safe harbor statement noting forward-looking statements are based on management expectations and are subject to risks. The presentation summarizes Topotarget's focus on developing belinostat to treat cancer, its partnerships including with Spectrum Pharmaceuticals to develop belinostat in the US, and its strategy to continue establishing belinostat as an effective treatment for cancers like PTCL by analyzing late-stage study results and exploring ex-US commercial opportunities.
Oriola-KD provides pharmaceutical distribution and retail services in Sweden, Finland and the Baltic countries. In 2015, Oriola-KD launched a new online shop in Sweden, expanded into healthcare services with an acquisition, and implemented a new operating model and strategy to improve efficiency. Key events and financial results were positive, with invoicing increasing and good cash flow. However, profitability was impacted by declines in parallel drug imports and price reductions in Sweden. Going forward, Oriola-KD aims to further develop its digital services, healthcare business, and achieve operational efficiencies.
Oriola-KD operates as an effective and reliable channel between pharmaceutical manufacturers and consumers in Northern Europe. Oriola-KD engages in pharmaceutical retailing, i.e. pharmacy operations, in Sweden, online pharmacy business in Latvia and pharmaceutical wholesaling and distribution in Finland, Sweden and the Baltic countries. In addition Oriola-KD markets health and well-being products in Finland and the Baltic countries. Oriola-KD’s net sales for 2014 were approximately EUR 1.6 billion. Company has approximately 2 350 employees. Oriola-KD is listed on NASDAQ OMX Helsinki Ltd.
This document discusses economic growth in various regions and lessons learned from Swedish policies. It finds that while China aims for 7% annual growth, Northern Europe faces slower growth. The Baltic Sea Region remains prosperous but heterogeneous. Swedish policies focus on improving access to finance for SMEs, commercialization, internationalization, and reducing regulations. Evaluations found regional venture capital funds in Sweden addressed financing gaps and supported company growth and professionalization. The document recommends continued policies to finance early-stage SMEs, encourage commercialization and internationalization, and improve regulations.
The document summarizes recent policy initiatives in Sweden to promote entrepreneurship and innovation. Key policies focus on improving the business environment through tax incentives and deregulation. Specific programs support entrepreneurship in healthcare, creative industries, and targeted groups. A new innovation strategy embraces broad concepts across sectors to address societal challenges through competitiveness and public service efficiency. Collaboration with Nordic countries aims to develop comparable data and indicators to evaluate framework conditions and priorities.
WSP Group is a global design, engineering and management consultancy. We work with clients to create built and natural environments for the future.
Introduce our new strategy plan
Meet our executive directors and hear about
their businesses:
Rikard Appelgren, European Managing
Director
Stuart McLachlan, Managing Director,
Environment & Energy
Paul Dollin, UK Managing Director
Insight into a major project: Crossrail,
Bond Street Station
Sweden has a decentralized healthcare system with 21 county councils and 290 municipalities. It utilizes 106 national quality registries to track patient outcomes, collect individualized data on problems, treatments, and outcomes. Funding is shared between regions and the government. Registries are organized with various groups and supported by 6 registry centers providing IT, analytics, and other services. Registries have grown substantially since 1979 and are used for active follow-up, quality improvement, research, and management. They have improved outcomes for issues like tonsil surgery and malnutrition screening. Factors in their success include registry management, multi-stakeholder involvement, and continuous use of data for analysis and improvement.
Royal Wessanen focused its portfolio on organic food between 2009 and 2012, selling off non-core brands. In 2012, it reported revenue of €710.8 million but an operating loss of €45.8 million due to impairment charges. It is implementing a transformation program called "Wessanen 2015" to become more profitable and efficient by focusing on its core brands and categories, simplifying processes, and addressing underperforming business areas. Royal Wessanen's vision is to build the most desired organic brands in Europe by offering products that are healthy, ethical, sustainable, functional, and authentic tasting.
Parallel Session 2.7 Working Collectively to Make Best Use of Our Resources A...NHSScotlandEvent
Here are the main people issues I see with change in procurement and HR, and some suggestions for bridging the gap between early adopters and those less keen to change:
- Fear of job loss or change. Reassure staff that the goal is not to reduce headcount but to work more efficiently. Provide training to help people take on new roles.
- Resistance to new ways of working. Clearly communicate the benefits of changes for both the organization and individuals. Involve skeptical staff in designing solutions to gain buy-in.
- Lack of understanding of the "why". Educate all staff on the strategic drivers and how their roles fit in. Show how changes ultimately improve patient care.
- Different p
This document analyzes opportunities and challenges for the drug Inspra to unlock its value. There are current opportunities such as resonating risk messages in new markets and achieving sales budgets in Germany. Challenges include a relatively small market for its approved indications and difficulties differentiating from generics. Strategic scenarios are proposed ranging from expanding indications and reducing price to limited support. Developing an FDC for Inspra is discussed to treat more patients and conditions. An analytical framework assesses demand forecasts, pricing research, and optimal scenarios. A limited R-HTN opportunity in the EU is identified that could increase revenues by focusing education and tactics on Inspra's critical success factors in approved markets and conditions.
This document discusses the Konsument Europa/European Consumer Centre in Sweden and its role in assisting consumers with cross-border disputes. It provides 3 key points:
1) The ECC in Sweden is part of a European network that assists consumers in resolving cross-border complaints against businesses in other EU/EEA countries through alternative dispute resolution.
2) It discusses the National Board for Consumer Disputes in Sweden as an alternative dispute resolution body that handles both domestic and cross-border cases, providing examples of cases involving consumers from Norway and Estonia.
3) Statistics are presented on the number and types of cross-border cases the ECC in Sweden and the National Board have handled from 2009-2013, with
Letícia | Phone: 55 (21) 4009-0276 | E-mail: leticia@profarma.com.br
Market Maker: BTG Pactual | Phone: 55 (11) 3383-2384
Ticker: BM&FBOVESPA: PRMX3
Independent Auditors: KPMG
Thank you for your interest in Profarma. Please contact us if you have any other questions.
- The document presents a marketing plan by Valor Consulting Inc. to expand into the real estate markets of Sweden, Netherlands, and Germany.
- It includes analyses of the cultural, political, economic, and competitive landscapes of Canada and Sweden. Strengths and weaknesses of competitors are also examined.
- The marketing plan proposes a product, pricing, placement, and promotion strategy focused on gaining attention, building trust, and adapting to the Swedish market.
- An action plan and contingency plan with timelines and budgets are put forward to gradually increase revenues in Sweden while maintaining high retention rates.
- The document presented plans by various members of a consulting team for expanding a Canadian real estate company into new European markets.
- An economic and competitive analysis of Canada, Sweden, and other target countries was conducted to evaluate growth opportunities.
- A marketing plan was proposed to introduce the company's customizable office space products and services in Sweden through various promotional strategies.
- An action plan and contingency budget were put forward outlining targets for the Swedish portfolio over multiple years and alternatives if economic conditions change.
KappAhl reported financial results for Q2 2005/06 with sales increasing 7.7% to SEK 1,026m driven by store expansion and favorable foreign exchange impacts. Gross profit grew 13.7% and margin improved to 57.4% due to better purchase prices and sell through. Operating profit increased 39.7% to SEK 88m however net profit was SEK 19m, impacted by SEK 40m in one-time IPO and refinancing costs. Management sees continued positive private spending and store expansion remaining on track as key drivers for business.
Dixons Retail reported a 3% decline in total underlying sales and a 5% drop in like-for-like sales for the 12 weeks ending January 7, 2012. However, its UK operations outperformed competitors with strong pre-Christmas sales and a 2% increase in like-for-like sales for the first two weeks of January. Multichannel sales grew 19% as online sales increased. The Nordic operations continued gaining market share through less aggressive pricing. However, operations in Italy and Greece struggled due to weak local economies. Gross margins remained flat year-over-year and inventory levels decreased 7%.
Mark Cahill, Global Vision National Diabetic Retinopathy Screening ProgrammeInvestnet
This document summarizes Ireland's National Diabetic Retinal Screening Programme. It discusses that diabetic retinopathy is a leading cause of blindness and annual screening can prevent blindness in 96% of cases. The programme screens over 145,000 people with diabetes annually using digital photographs of the retina that are graded by qualified reviewers. Those found to have signs of diabetic retinopathy or macular edema are referred to hospital treatment centers for further evaluation and care. The programme aims to screen 30% of the eligible population in its first year and 70% in the second year.
This document provides an overview of a life science seminar presented by Topotarget A/S executives. It includes a safe harbor statement noting forward-looking statements are based on management expectations and are subject to risks. The presentation summarizes Topotarget's focus on developing belinostat to treat cancer, its partnerships including with Spectrum Pharmaceuticals to develop belinostat in the US, and its strategy to continue establishing belinostat as an effective treatment for cancers like PTCL by analyzing late-stage study results and exploring ex-US commercial opportunities.
Oriola-KD provides pharmaceutical distribution and retail services in Sweden, Finland and the Baltic countries. In 2015, Oriola-KD launched a new online shop in Sweden, expanded into healthcare services with an acquisition, and implemented a new operating model and strategy to improve efficiency. Key events and financial results were positive, with invoicing increasing and good cash flow. However, profitability was impacted by declines in parallel drug imports and price reductions in Sweden. Going forward, Oriola-KD aims to further develop its digital services, healthcare business, and achieve operational efficiencies.
Oriola-KD operates as an effective and reliable channel between pharmaceutical manufacturers and consumers in Northern Europe. Oriola-KD engages in pharmaceutical retailing, i.e. pharmacy operations, in Sweden, online pharmacy business in Latvia and pharmaceutical wholesaling and distribution in Finland, Sweden and the Baltic countries. In addition Oriola-KD markets health and well-being products in Finland and the Baltic countries. Oriola-KD’s net sales for 2014 were approximately EUR 1.6 billion. Company has approximately 2 350 employees. Oriola-KD is listed on NASDAQ OMX Helsinki Ltd.
This document discusses economic growth in various regions and lessons learned from Swedish policies. It finds that while China aims for 7% annual growth, Northern Europe faces slower growth. The Baltic Sea Region remains prosperous but heterogeneous. Swedish policies focus on improving access to finance for SMEs, commercialization, internationalization, and reducing regulations. Evaluations found regional venture capital funds in Sweden addressed financing gaps and supported company growth and professionalization. The document recommends continued policies to finance early-stage SMEs, encourage commercialization and internationalization, and improve regulations.
The document summarizes recent policy initiatives in Sweden to promote entrepreneurship and innovation. Key policies focus on improving the business environment through tax incentives and deregulation. Specific programs support entrepreneurship in healthcare, creative industries, and targeted groups. A new innovation strategy embraces broad concepts across sectors to address societal challenges through competitiveness and public service efficiency. Collaboration with Nordic countries aims to develop comparable data and indicators to evaluate framework conditions and priorities.
WSP Group is a global design, engineering and management consultancy. We work with clients to create built and natural environments for the future.
Introduce our new strategy plan
Meet our executive directors and hear about
their businesses:
Rikard Appelgren, European Managing
Director
Stuart McLachlan, Managing Director,
Environment & Energy
Paul Dollin, UK Managing Director
Insight into a major project: Crossrail,
Bond Street Station
Sweden has a decentralized healthcare system with 21 county councils and 290 municipalities. It utilizes 106 national quality registries to track patient outcomes, collect individualized data on problems, treatments, and outcomes. Funding is shared between regions and the government. Registries are organized with various groups and supported by 6 registry centers providing IT, analytics, and other services. Registries have grown substantially since 1979 and are used for active follow-up, quality improvement, research, and management. They have improved outcomes for issues like tonsil surgery and malnutrition screening. Factors in their success include registry management, multi-stakeholder involvement, and continuous use of data for analysis and improvement.
Royal Wessanen focused its portfolio on organic food between 2009 and 2012, selling off non-core brands. In 2012, it reported revenue of €710.8 million but an operating loss of €45.8 million due to impairment charges. It is implementing a transformation program called "Wessanen 2015" to become more profitable and efficient by focusing on its core brands and categories, simplifying processes, and addressing underperforming business areas. Royal Wessanen's vision is to build the most desired organic brands in Europe by offering products that are healthy, ethical, sustainable, functional, and authentic tasting.
Parallel Session 2.7 Working Collectively to Make Best Use of Our Resources A...NHSScotlandEvent
Here are the main people issues I see with change in procurement and HR, and some suggestions for bridging the gap between early adopters and those less keen to change:
- Fear of job loss or change. Reassure staff that the goal is not to reduce headcount but to work more efficiently. Provide training to help people take on new roles.
- Resistance to new ways of working. Clearly communicate the benefits of changes for both the organization and individuals. Involve skeptical staff in designing solutions to gain buy-in.
- Lack of understanding of the "why". Educate all staff on the strategic drivers and how their roles fit in. Show how changes ultimately improve patient care.
- Different p
This document analyzes opportunities and challenges for the drug Inspra to unlock its value. There are current opportunities such as resonating risk messages in new markets and achieving sales budgets in Germany. Challenges include a relatively small market for its approved indications and difficulties differentiating from generics. Strategic scenarios are proposed ranging from expanding indications and reducing price to limited support. Developing an FDC for Inspra is discussed to treat more patients and conditions. An analytical framework assesses demand forecasts, pricing research, and optimal scenarios. A limited R-HTN opportunity in the EU is identified that could increase revenues by focusing education and tactics on Inspra's critical success factors in approved markets and conditions.
This document discusses the Konsument Europa/European Consumer Centre in Sweden and its role in assisting consumers with cross-border disputes. It provides 3 key points:
1) The ECC in Sweden is part of a European network that assists consumers in resolving cross-border complaints against businesses in other EU/EEA countries through alternative dispute resolution.
2) It discusses the National Board for Consumer Disputes in Sweden as an alternative dispute resolution body that handles both domestic and cross-border cases, providing examples of cases involving consumers from Norway and Estonia.
3) Statistics are presented on the number and types of cross-border cases the ECC in Sweden and the National Board have handled from 2009-2013, with
Letícia | Phone: 55 (21) 4009-0276 | E-mail: leticia@profarma.com.br
Market Maker: BTG Pactual | Phone: 55 (11) 3383-2384
Ticker: BM&FBOVESPA: PRMX3
Independent Auditors: KPMG
Thank you for your interest in Profarma. Please contact us if you have any other questions.
- The document presents a marketing plan by Valor Consulting Inc. to expand into the real estate markets of Sweden, Netherlands, and Germany.
- It includes analyses of the cultural, political, economic, and competitive landscapes of Canada and Sweden. Strengths and weaknesses of competitors are also examined.
- The marketing plan proposes a product, pricing, placement, and promotion strategy focused on gaining attention, building trust, and adapting to the Swedish market.
- An action plan and contingency plan with timelines and budgets are put forward to gradually increase revenues in Sweden while maintaining high retention rates.
- The document presented plans by various members of a consulting team for expanding a Canadian real estate company into new European markets.
- An economic and competitive analysis of Canada, Sweden, and other target countries was conducted to evaluate growth opportunities.
- A marketing plan was proposed to introduce the company's customizable office space products and services in Sweden through various promotional strategies.
- An action plan and contingency budget were put forward outlining targets for the Swedish portfolio over multiple years and alternatives if economic conditions change.
KappAhl reported financial results for Q2 2005/06 with sales increasing 7.7% to SEK 1,026m driven by store expansion and favorable foreign exchange impacts. Gross profit grew 13.7% and margin improved to 57.4% due to better purchase prices and sell through. Operating profit increased 39.7% to SEK 88m however net profit was SEK 19m, impacted by SEK 40m in one-time IPO and refinancing costs. Management sees continued positive private spending and store expansion remaining on track as key drivers for business.
Dixons Retail reported a 3% decline in total underlying sales and a 5% drop in like-for-like sales for the 12 weeks ending January 7, 2012. However, its UK operations outperformed competitors with strong pre-Christmas sales and a 2% increase in like-for-like sales for the first two weeks of January. Multichannel sales grew 19% as online sales increased. The Nordic operations continued gaining market share through less aggressive pricing. However, operations in Italy and Greece struggled due to weak local economies. Gross margins remained flat year-over-year and inventory levels decreased 7%.
Mark Cahill, Global Vision National Diabetic Retinopathy Screening ProgrammeInvestnet
This document summarizes Ireland's National Diabetic Retinal Screening Programme. It discusses that diabetic retinopathy is a leading cause of blindness and annual screening can prevent blindness in 96% of cases. The programme screens over 145,000 people with diabetes annually using digital photographs of the retina that are graded by qualified reviewers. Those found to have signs of diabetic retinopathy or macular edema are referred to hospital treatment centers for further evaluation and care. The programme aims to screen 30% of the eligible population in its first year and 70% in the second year.
Läs Ortho Center Stockholm Verksamhets- och kvalitetsrapport.
Under 2011 bibehöll vi vår position som den största enskilda producenten av höft- och knäledsplastiker inom vårdvalet i Stockholms Län.
Global Health Partner
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
3. Highlights Q1 2012
• Revenue increased with 8% to SEK 192,4 million (178,9) during Q1
• Operating result (EBIT) amounted to SEK 5,0 million (10,4) in Q1
• Operation result (EBIT) amounted to SEK 7,6 million, excluding Danish
acquisition costs
• Profitability affected by continued tough market situation in Bariatrics
• Acquisition of Gildhöj during December effective from 1 February 2012
3
4. Market factors
Sweden
•Prices have stabilized, - 20% vs 2011
•Tendered wait list contracts not yet in use
Denmark
Bariatrics
•Complete patient drainage following new criteria
Czech Republic
•Slightly better prices 2012, strong demand
Spine
Sweden
•Riksavtalet – new policy that allows all counties to use
“lowest tendered prices”
Orthopaedics
•Västra Götaland is opposing government free choice policies
Dental •Demand is stable
4
5. Market factors- looking ahead
Current situation Measures
Sweden Sweden
• Same as 2011 • Further cost reduction
Denmark Denmark
• Same as 2011 • Closure of unit in Q2
Bariatrics
Czech Republic Czech Republic
• Slightly better 2012 • Completed action plan
Finland, Norway, Cairo and UAE Finland, Norway, Cairo and UAE
• Continued slow but positive development • No measure taken
Result: Still demanding but turn around under control
Riksavtalet, actions taken
Spine
Västra Götaland deletion of free choice planning political actions
Orthopaedics
Result: Continued increased demand, no further price erosion expected but red flag for
Ortho Center Göteborg and Spine Center Stockholm
5
6. Market factors – Current situation and measures taken, cont.
Current situation Measures
Sweden Sweden
Dental • Stable demand, less complexity • Cost reduction/consolidation
• Continued market share increase
Sweden Sweden
Arrhythmia • Increased demand • No measures taken
• Price erosion expected if volumes take off
Sweden Sweden
Gastro • Continued increased demand • No measures taken
• Stable prices
6
7. Market factors – Summary
2011 2012
• Strong negative impact – • Less turbulence
forcing actions • Some negative factors reside
• Compensated by growth
in Spine/Ortho, Arrhythmia
and Gastro
One serious new red flag, Västra Götaland policy changes
7
8. Our strategy can be summarized in four cornerstones
“Quality through
Partnership
Specialisation” –
model
Service Lines
Decentralised Rapid growth in
business model selected markets
8
9. GHP Service Lines
• Spine surgery/spine care
Spine • 4 clinics in Sweden, Norway and Denmark (Orthopaedics/Spine)
• Sports traumatology and prosthetic surgery
Orthopaedics
• 5 clinics in Sweden and Denmark (Orthopaedics/Spine)
• Specialist dentistry
Dental • 3 clinics in Sweden
• Treatment and surgery of obesity and reconstructive plastic surgery
Bariatrics • 11 clinics in Sweden, Finland, Denmark, Norway, Czech Republic, Egypt and UAE
• Medical gastroenterology and endoscopy
Gastro
• 3 clinics in Sweden
• Disturbance of the heart rhythm
Arrhythmia • 1 clinic in Sweden
9
10. GHP clinics
Spine
Dental
Bariatrics
RASHID CENTRE FOR DIABETES
& RESEARCH
Gastro
STOCKHOLM GASTRO CENTER
paedics
Ortho-
Arrhythmia
10
11. Continued challenging market conditions
SEK millions
Revenue
• Revenue increased from SEK 179 million to SEK 192 million
Q1
for Q1 2012, which corresponds to 8 percent growth
• All Service Lines, except Bariatrics, contributes to growth for Q1
• Strong demand in all Swedish Ortho and Spine clinics.
• Organic growth in Q1 was negative (-2 percent) due to reduction of 8 % growth Q1
179 192
revenues in Bariatrics.
• Severe drop in both Swedish Bariatrics clinics, price pressure and
changed patient mix are main reasons.
• Delayed patient flow to Bariatric Center Stockholm from newly won
2011 2012
contract with VGR.
700
Revenue rolling 12 months 689
600 666 675
624 646
• Rolling 12 months continue to increase and 500 586
503 518 544
559 2012:
now amounts to SEK 689 million. 400 2011: 8%
300 2010: 15%
• The acquisition of OPA and Gildhöj has helped growth 17%
200 2009
for the first quarter. 26%
100
0
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
2009 2010 2011 2012
11
12. Profitability kept down by Bariatrics
SEK millions
EBIT
Q1
• Operating result in Q1 decreased due to continued tough market
situation for Bariatrics in the Nordics.
• EBIT reduced with acquisition costs in Denmark of 2,6 million for
completed and ongoing acquisitions. 10,4
• Strong performance in Swedish Spine, Orthopaedics, Dental and
Arrhythmia clinics. 5,0
• The clinic in Prague has minimal impact on group EBIT after successful
restructuring of ownership and increased performance. 2011 2012
EBIT, rolling 12 months EBIT, rolling 12 months
34
32
35 28
• A SEK 5 million reduction leads to rolling 24
12 months EBIT of SEK 10 million 25
15
13
15 10
4
5
-5 -2
-8 -7 -6
-15
Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
2009 2010 2011 2012
12
13. Reduced profit margin
SEK millions
EBIT margin Per
quarter
• Q1 EBIT margin was reduced from 5,8 percent to 2,6 Rolling 12
10%
percent.
5%
• However, margin increased compared to the second
half of 2011. 0%
-5%
• EBIT margin for rolling 12 months decreased from 2,2
percent to1,4 percent. -10%
-15%
• 2009 numbers are shown exclusive of UK one-off costs
-20%
Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
2009 2010 2011 2012
EBIT trend
20 15,3
• Q3 2011 showed a drop in EBIT compared to the 12,5 13
8,7 10,4
corresponding period during previous year. Q4 10 5,5 4,7 5
3,5
continued the negative trend, but Q1 2012 was a
step in the right direction. 0
-10 -4,1
• 2009 numbers are shown exclusive of UK
-11,7
one-off costs -20
-13,1
Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
2009 2010 2011 2012
13
14. Performance per Service Line – Q1
Service Line Spine/Orthopaedics
• Solid organic growth in the Swedish Orthopaedic clinics Q1 Q1 Full year Full year
SEK million 2012 2011 Change 2011 2010
despite low prices in the Stockholm market.
Revenues 124,0 97,5 27 % 379,6 320,5
• Strong profitability in all Swedish clinics. Operating result 12,5 14,1 35,3 41,5
Operating margin, % 10 14 9 13
• The acquisitions of OPA and Gildhöj have a significant
impact on the revenues in Q1, but OPA affects the
profitability negatively in Q1.
Service Line Dental
Q1 Q1 Full year Full year
• Solid growth despite continued decline in market for SEK million 2012 2011 Change 2011 2010
dental implants. Revenues 25,4 22,3 14 % 92.3 96.4
• Internal reorganization is completed and new Operating result 2,1 1,2 6.5* 10.3
management and new structure is in place. Operating margin, % 8 5 7 11
* before goodwill write-downs
• EBIT improvement in Q1 is a promising start of 2012.
14
15. Performance per Service Line, cont.
Service Line Bariatrics
Q1 Q1 Full year Full year
• The market is still very tough and is characterized by SEK million 2012 2011 Change 2011 2010
high price pressure and low patient flow for the Swedish Revenues 35,0 51,4 -32 % 174,7 143,7
clinics. Operating result -3,8 1,4 -0,2 4,0
• The clinic in Prague has been deconsolidated due to Operating margin, % -11 3 0 3
an issue of shares to a new main owner, and is picking
up in performance.
• Post balance sheet events: It was decided to close clinic
in Copenhagen due to continued lack of patients.
Service Line Arrhythmia Q1 Q1 Full year Full year
SEK million 2012 2011 Change 2011 2010
• Solid growth and profitability
Revenues 8,0 7,7 4% 28,6 24,9
• Stable future patient flow is expected. Operating result 1,3 1,3 2,8 2,9
Operating margin, % 16 17 10 12
15
16. Performance per geograpic area – Q1
SEK millions
Q1 Q1 Full year Full year
2012 2011 2011 2010
Revenue from business activities 157,7 157,4 577.2 526.5
Sweden
Operating result from business activities 9,2 10,6 30.4 35.8
Revenue from business activities 30,0 13,5 66.0 31.7
Nordic
region
Operating result from business activities -5,6 0,4 -12.6 -2.7
Revenue from business activities 4,7 8.0 32.0 27.3
Other
countries
Operating result from business activities 1,4 -0,6 -2.6 -4.7
Reported operating result* 5,0 10,4 15.2 28.4
Comments
• All business development costs are included in the Swedish segment
• Swedish business is affected negatively from tough market situation in Bariatrics in the Nordics.
• The business in Other countries has reduced revenues and improved EBIT due to the deconsolidation of the clinic in
Prague.
* All numbers excl. goodwill write downs
16
17. Reduced margins in mature business – Q1
SEK millions
Q1 Q1 Full year Full year
2012 2011 2011 2010
Revenue 185,4 160,0 625.8 495.6
Mature business
Operating result 18,9 21,0 67.0 63.1
Newly opened Revenue 7,0 18,9 49.4 89.9
and development
Operating result -13,9 -10,6 -51.8 -34.7
Reported revenue 192,4 178,9 675,2 585,5
Reported operating result* 5,0 10,4 15,2 28.4
Comments
• Mature clinics are clinics that have been in operation for at least 24 months
• Central administration costs for the Group are included in the mature business
• Central expansion and project costs are included in the Newly opened and development business
• Increased costs for newly opened clinics and projects, mainly in Bariatrics Denmark.
* All numbers excl. goodwill write downs
17
18. Financial key data – Q1
SEK millions
Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
2012 2011 2011 2011 2011 2010 2010 2010 2010 2009 2009 2009 2009
Total cash 75 98 95 121 139 137 133 145 152 163 155 190 198
Shareholders equity incl.
403 409 439 451 455 475 515 522 514 513 511 550 547
minority
Long term debt 247 236 252 262 263 253 131 134 129 136 115 119 116
Net cash position -102 -58 -66 -11 7 14 9 20 33 36 23 62 76
Equity ratio 50 % 54% 54% 55% 54% 54% 68% 67% 69% 68% 67% 69% 70%
Net debt / EBITDA rolling 12 2,7 1.4 1.3 0.19 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Int bearing debt / EBITDA
4,9 3.8 3.2 2.4 2.4 2.5 4.0 6.1 11.7 16.8 11.6 28.9
rolling 12
Int bearing debt / adjusted
4,9 3.8 3.2 2.4 2.4 2.5 2.9 3.9 5.5 6.7 9.9 10.9
EBITDA rolling 12
EPS -0,05 -0.46 -0.19 0.09 0.04 0.13 -0.07 0.09 -0.01 -0.19 -0.19 -0.01 -0.06
Basic cash flow from
operating activities per -0,12 0.17 -0.27 0.19 0.00 0.38 -0.07 0.08 0.03 0.32 -0.32 0.05 -0.08
share
Shareholders equity per
6,08 6.18 6.65 6.83 6.84 6.81 7.41 7.53 7.44 7.45 7.55 7.8 7.77
share, SEK
Number of employees 355 372 364 360 367 324 306 302 297 288 281 282 279
Revenue per employee 0,54 0.50 0.35 0.50 0.49 0.55 0.36 0.52 0.47 0.52 0.33 0.47 0.45
Note: The equity ratio has been re-calculated from the period Q4 2010 and onwards as a result of the change in accounting for put options.
18
19. Temporary increase in working capital – Q1
SEK millions
Comments Q1 2011
20
Q1 2012
• Temporary weak operating cash flow in the first
10
quarter
0
• Cash flow from investing activities mainly
-1 0
consists of investments in health care
equipment and acquisitions of shares in -2 0
subsidiaries -3 0
• Cash flow from financing activities include -4 0
new loans as well as some loan repayments Operations Investments Financing Cash flow
19
20. www.globalhealthpartner.com
Contact:
Per Båtelson, CEO, +46 (0)705-95 57 00, per.batelson@ghpartner.com
Tobias Linebäck, CFO and IR, +46 (0)708-55 37 19, tobias.lineback@ghpartner.com
20